<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Between June 1981 and May 1988, 51 children with diffuse undifferentiated, advanced (Murphy Stage III and IV) intra-abdominal non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were treated on an intensive multi-drug chemotherapy protocol without irradiation to the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumour</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Therapy was completed for Stage III disease at one year, but Stage IV patients continued with a further year of therapy until January 1986, when it was reduced to one year </plain></SENT>
<SENT sid="2" pm="."><plain>Central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) prophylaxis consisted of eight doses of intrathecal MTX for <z:hpo ids='HP_0000001'>all</z:hpo> children, and 24 Gy cranial irradiation for Stage IV patients only </plain></SENT>
<SENT sid="3" pm="."><plain>There were 42 patients with Stage III disease (III A n = 29 and III B n = 13) and nine patients with Stage IV disease, of whom eight had extensive bone marrow and extramedullary disease (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">FAB L3</z:e> ALL) </plain></SENT>
<SENT sid="4" pm="."><plain>No patient had <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> disease at presentation </plain></SENT>
<SENT sid="5" pm="."><plain>Forty-eight of 51 children (94%) achieved a complete remission </plain></SENT>
<SENT sid="6" pm="."><plain>Two children died during remission induction therapy and eleven children relapsed, mostly within eight months of diagnosis </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients have completed therapy </plain></SENT>
<SENT sid="8" pm="."><plain>Failure free survival is 76% for Stage III and 67% for Stage IV patients, with a median followup of 90 and 64 months, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Subdividing Stage III patients into Stage III A and III B did not show significantly different survival (P = 0.9), but the number of patients in Stage III B is small </plain></SENT>
<SENT sid="10" pm="."><plain>These results compare favourably with the most effective published protocols, and toxicity has been manageable </plain></SENT>
</text></document>